Color Atlas of Hematology
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Endogenous Dendritic Cells from the Tumor Microenvironment Support T
Endogenous dendritic cells from the tumor PNAS PLUS microenvironment support T-ALL growth via IGF1R activation Todd A. Tripletta, Kim T. Cardenasa,1, Jessica N. Lancastera, Zicheng Hua, Hilary J. Seldena, Guadalupe J. Jassoa, Sadhana Balasubramanyama, Kathy Chana, LiQi Lib, Xi Chenc,d, Andrea N. Marcogliesee, Utpal P. Davéf, Paul E. Loveb, and Lauren I. R. Ehrlicha,2 aDepartment of Molecular Biosciences, Institute for Cellular and Molecular Biology, The University of Texas at Austin, Austin, TX 78712; bSection on Hematopoiesis and Lymphocyte Biology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892; cDivision of Biostatistics, Department of Health Sciences, University of Miami Miller School of Medicine, Miami, FL 33136; dSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136; eDepartment of Pathology and Immunology, Baylor College of Medicine, Houston, TX 77030; and fDivision of Hematology/Oncology, Tennessee Valley Healthcare System and Vanderbilt University Medical Center, Nashville, TN 37232 Edited by Zena Werb, University of California, San Francisco, CA, and approved January 14, 2016 (received for review October 15, 2015) Primary T-cell acute lymphoblastic leukemia (T-ALL) cells require tumor growth and metastasis (3). Tumor-associated macrophages stromal-derived signals to survive. Although many studies have (TAMs), which resemble alternatively activated (M2) macro- identified cell-intrinsic alterations in signaling pathways that promote phages (4), also support tumor growth. TAMs suppress antitumor T-ALL growth, the identity of endogenous stromal cells and their immune responses, promote tumor invasion and angiogenesis, and associated signals in the tumor microenvironment that support T-ALL are negatively associated with clinical outcomes (5). -
PATHOLOGY RESIDENT HEMATOLOGY ROTATION (North Florida/South Georgia Veterans Health Care System): Rotation Director: William L
PATHOLOGY RESIDENT HEMATOLOGY ROTATION (North Florida/South Georgia Veterans Health Care System): Rotation Director: William L. Clapp, M.D., Chief, Hematology Section, Gainesville VAMC; Consultants: Neil S. Harris, M.D., Director, Laboratory Hematology/Coagulation, University of Florida and Shands Hospital and Raul C. Braylan, M.D., Director, Hematopathology, University of Florida and Shands Hospital 1. Description of the Rotation: In this rotation, the resident will gain experience in laboratory hematology, which will include (1) peripheral blood studies to evaluate a variety of hematologic disorders, including anemias, lymphoproliferative and myeloproliferative disorders and leukemias. The emphasis on a multidisciplinary approach to diagnose hematologic disorders (including correlation of the peripheral blood studies with bone marrow and lymph node studies) provides an opportunity for the resident to also gain additional experience in (2) traditional histopathology, (3) immunohistochemistry, (4) electron microscopy, (5) protein electrophoresis, (6) flow cytometry, (7) cytogenetics and (8) molecular genetics which may be performed on the peripheral blood, bone marrow or lymph nodes of patients. The residents will acquire valuable experience by independently performing some bone marrow procedures. In addition, the resident will gain experience in coagulation testing. The residents will become familiar with the instrumentation in the hematology laboratory, including the operating principles and trouble-shooting (medical knowledge). The availability of assembled case study sets and reading materials (medical knowledge) will enhance the resident’s experience. Participation in CAP surveys, continuing education and hematology conferences is a component of the rotation (practice-based learning). Management issues and computer applications will be discussed (practice-based learning). As appropriate to the individual case or consultation under review, the ethical, socioeconomic, medicolegal and cost-containment issues will be reviewed and discussed. -
Section 8: Hematology CHAPTER 47: ANEMIA
Section 8: Hematology CHAPTER 47: ANEMIA Q.1. A 56-year-old man presents with symptoms of severe dyspnea on exertion and fatigue. His laboratory values are as follows: Hemoglobin 6.0 g/dL (normal: 12–15 g/dL) Hematocrit 18% (normal: 36%–46%) RBC count 2 million/L (normal: 4–5.2 million/L) Reticulocyte count 3% (normal: 0.5%–1.5%) Which of the following caused this man’s anemia? A. Decreased red cell production B. Increased red cell destruction C. Acute blood loss (hemorrhage) D. There is insufficient information to make a determination Answer: A. This man presents with anemia and an elevated reticulocyte count which seems to suggest a hemolytic process. His reticulocyte count, however, has not been corrected for the degree of anemia he displays. This can be done by calculating his corrected reticulocyte count ([3% × (18%/45%)] = 1.2%), which is less than 2 and thus suggestive of a hypoproliferative process (decreased red cell production). Q.2. A 25-year-old man with pancytopenia undergoes bone marrow aspiration and biopsy, which reveals profound hypocellularity and virtual absence of hematopoietic cells. Cytogenetic analysis of the bone marrow does not reveal any abnormalities. Despite red blood cell and platelet transfusions, his pancytopenia worsens. Histocompatibility testing of his only sister fails to reveal a match. What would be the most appropriate course of therapy? A. Antithymocyte globulin, cyclosporine, and prednisone B. Prednisone alone C. Supportive therapy with chronic blood and platelet transfusions only D. Methotrexate and prednisone E. Bone marrow transplant Answer: A. Although supportive care with transfusions is necessary for treating this patient with aplastic anemia, most cases are not self-limited. -
Acquired Hemophilia A: Pathogenesis and Treatment
Bleeding disorders Acquired hemophilia A: pathogenesis and treatment P.W. Collins ABSTRACT Arthur Bloom Haemophilia Centre, Acquired hemophilia A is an autoimmune disease caused by an inhibitory antibody to factor VIII. The School of Medicine, severity of bleeding varies but patients remain at risk of life-threatening bleeding until the inhibitor Cardiff University, Heath Park, has been eradicated. The cornerstones of management are rapid and accurate diagnosis, control of Cardiff, UK bleeding, investigation for an underlying cause, and eradication of the inhibitor by immunosuppres - sion. Patients should be managed jointly with a specialist center even if they present without signifi - cant bleeding. Despite an extensive literature, few controlled data are available and management Hematology Education: guidelines are based on expert opinion. Recombinant factor VIIa and activated prothrombin complex the education program for the concentrate are equally efficacious for treating bleeds and both are superior to factor VIII or desmo - annual congress of the European pressin. Immunosuppression should be started as soon as the diagnosis is made. Commonly used reg - Hematology Association imens are steroids alone or combined with cytotoxic agents. Rituximab is being used more commonly but current evidence does not suggest that it improves outcomes or reduces side effects. 2012;6:65-72 Introduction Pathogenesis Acquired hemophilia A (AHA) is a bleed - AHA is associated with autoimmune dis - ing disorder caused by polyclonal IgG1 and eases, such as rheumatoid arthritis, polymyal - IgG4 autoantibodies to the factor VIII ( FVIII ) gia rheumatic, and systemic lupus erythe - A2 and C2 domain. Morbidity and mortality matosis; malignancy; pregnancy and dermato - are high secondary to age, underlying dis - logical disorders, such as pemphigoid. -
Haemophilia a Is the Most Common Form – Affecting
Haemophilia is an inherited, serious It can dramatically reduce bleeding disorder where a person’s the quality of life of people blood does not clot properly, leading affected, as well as their family, to uncontrolled bleeding which can friends and caregivers1. occur spontaneously or after minor trauma. Haemophilia A is the most common form – affecting 50-60% of whom have severe haemophilia4. blood of a person In a healthy person, proteins called clotting factors work together to form a blood clot and help stop bleeding. People with haemophilia A either lack or do not have enough of a clotting factor called which leads to their blood not being able to clot properly. Bruising Repeated bleeding into muscles and joints, which can lead to long term disability or joint disease5 Spontaneous bleeding, which can be life threatening if it occurs in vital organs, such as the brain Prolonged and uncontrolled bleeding following injury or surgery6,7 Life for people with haemophilia and their caregivers is often centred on treatment infusions, taking up a large amount of time and having a significant impact on their lives8. People with haemophilia A report difficulty balancing treatment with daily life, so compliance can be a challenge9,10 leaving them vulnerable to potentially dangerous bleeds. The mainstay of current treatment for haemophilia A is factor VIII replacement therapy, which is taken on-demand (as needed to treat bleeds), or on an ongoing basis (to prevent bleeds). It is short-acting and so needs to be administered frequently (at least twice a week)2 by the patient or a caregiver and for some, especially children, finding a vein for medicine infusion can be difficult11. -
Outcomes of Patients with Thrombocytopenia Evaluated at Hematology Subspecialty Clinics
Henry Ford Health System Henry Ford Health System Scholarly Commons Hematology Oncology Articles Hematology-Oncology 2-11-2021 Outcomes of patients with thrombocytopenia evaluated at hematology subspecialty clinics Zaid H. Abdel Rahman Kevin C. Miller H Jabbour Yaser Alkhatib Vijayalakshmi Donthireddy Follow this and additional works at: https://scholarlycommons.henryford.com/ hematologyoncology_articles Hematol Oncol Stem Cell Ther xxx (xxxx) xxx Available at www.sciencedirect.com ScienceDirect journal homepage: www.elsevier.com/locate/hemonc Outcomes of patients with thrombocytopenia evaluated at hematology subspecialty clinics Zaid H. Abdel Rahman a,*, Kevin C. Miller b, Hiba Jabbour c, Yaser Alkhatib c, Vijaya Donthireddy c a Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL, USA b Department of Medicine, Massachusetts General Hospital, Boston, MA, USA c Division of Hematology and Medical Oncology, Henry Ford Hospital, Detroit, MI, USA Received 6 October 2020; received in revised form 9 December 2020; accepted 15 January 2021 KEYWORDS Abstract Hematology; Background: Thrombocytopenia is a frequently encountered laboratory abnormality and a Malignancy; common reason for hematology referrals. Workup for thrombocytopenia is not standardized Platelets; and frequently does not follow an evidence-based algorithm. We conducted a systematic anal- Referrals; Thrombocytopenia ysis to evaluate the laboratory testing and outcomes of patients evaluated for thrombocytope- nia at hematology clinics in a tertiary referral center between 2013 and 2016. Patient and methods: We performed a comprehensive chart review for patients evaluated for thrombocytopenia during the study period. Patients were followed for 1 year from the initial hematology evaluation and assessed for the development of a hematologic malignancy, rheumatologic, or infectious diseases among other clinical outcomes. -
WSC 20-21 Conf 6 Illustrated Results
Joint Pathology CenterJoint Pathology Center Veterinary PathologyVeterinary Services Pathology Services WEDNESDAY SLIDE CONFERENCE 2020-2021 WEDNESDAY SLIDE CONFERENCE 2019-2020 Conference 6 C o n f e r e n c e 16 29 January 2020 30 September 2020 Dr. Ingeborg Langohr, DVM, PhD, DACVP Professor Department of Pathobiological Sciences Louisiana State University School of Veterinary Medicine Joint Pathology Center Baton Rouge, LA Silver Spring, Maryland CASE I: CASE S1809996 1: N16 (JPC-032 4135077(4084301).-00 ) Microscopic2.2x1.5x2 Description: cm firm mass The originatinginterstitium from the dura within themater section (meningioma). is diffusely infiltrated by Signalment:Signalment: A 3-month 13- old,yrs male,of age, mixed spayed- female,moderate to large numbers of predominantly breed pigGolden (Sus scrofa Retriever,) Canis lupus familiaris, caninemononuclear. Laboratory cells along results: with edema. There is abundantCytology: type II pneumocyteIt was reported hyperplasia that ante -mortem History: This pig had no previous signs of History: lining alveolarcytology septae of blood and manysmears of from the this animal were illness, andIt waswas reportedfound dead. that the patient had decreased consistent with lymphoid leukemia. appetite and lethargy for the past 1-2 weeks andalveolar spacesSpecial have staining: central Under areas polarized of light, Congo Gross Pathologyhad diarrhea: Approximately for ~1 day. She70% had of a history ofnecrotic macrophagesRed special admixedstain withrevealed other apple-green the lungs,seizures primarily for thein the past cranial ~3 years; regions her last of seizure wasmononuclear birefringence cells and of fewer material neutrophils. effacing glomeruli and the lobes,1 were month patchy ago. darkThe red,patient and hadfirm a generalizedOccasionally cardiac there vessel is free. -
Alpha Thalassemia Trait
Alpha Thalassemia Trait Alpha Thalassemia Trait Produced by St. Jude Children’s Research Hospital, Departments of Hematology, Patient Education, 1 and Biomedical Communications. Funds were provided by St. Jude Children’s Research Hospital, ALSAC, and a grant from the Plough Foundation. This document is not intended to replace counseling by a trained health care professional or genetic counselor. Our aim is to promote active participation in your care and treatment by providing information and education. Questions about individual health concerns or specific treatment options should be discussed with your doctor. For general information on sickle cell disease and other blood disorders, please visit our Web site at www.stjude.org/sicklecell. Copyright © 2009 St. Jude Children’s Research Hospital Alpha thalassemia trait All red blood cells contain hemoglobin (HEE muh glow bin), which carries oxygen from your lungs to all parts of your body. Alpha thalassemia (thal uh SEE mee uh) trait is a condition that affects the amount of hemo- globin in the red blood cells. • Adult hemoglobin (hemoglobin A) is made of alpha and beta globins. • Normally, people have 4 genes for alpha globin with 2 genes on each chromosome (aa/aa). People with alpha thalassemia trait only have 2 genes for alpha globin, so their bodies make slightly less hemoglobin than normal. This trait was passed on from their parents, like hair color or eye color. A trait is different from a disease 2 Alpha thalassemia trait is not a disease. Normally, a trait will not make you sick. Parents who have alpha thalassemia trait can pass it on to their children. -
Lymph Node Cytology
Lymph node cytopathology : A practical approach to lymphoproliferative disorders • Koray Ceyhan, M.D • Department of Pathology • Faculty of Medicine • Ankara University • Ankara, Turkey Diagnostic use of FNA in lymph node pathologies • Well-established : • - metastatic malignancy, • - lymphoma recurrences • -some reactive or inflammatory disorders: Tuberculosis,sarcoidosis • Diagnostic sensitivity/accuracy : usually above 95% • Controversial: • primary lymphoma diagnosis • Diagnostic sensitivity varies from 12% to 96% Academic institutions: high level diagnostic accuracy Community practise the accuracy rate significantly low Multiparameter approach is critical for definitive lymphoma diagnosis • Cytomorphologic features alone are not sufficient for the diagnosis of primary lymphoma • Immunophenotyping with flow cytometry and/or immunocytochemistry is mandatory • In selected cases molecular/cytogenetic analyses are required for definitive lymphoma classification Lymph node pathologies • 1-Reactive lymphoid hyperplasia/inflammatory disorders • 2-Lymphoid malignancies • 3-Metastatic tumors 1 3 2 Common problems in lymph node cytology • Reactive lymphoid hyperplasia vs lymphoma • Primary lymphoma diagnosis(lymphoma subtyping) • Predicting primary site of metastatic tumor • Nonlymphoid tumors mimicking lymphoid malignancies • Correct diagnosis of specific benign lymphoid lesions Problem 1: Reactive vs lymphoma Case 19- years-old boy Multiple bilateral cervical LAPs for 4 weeks FNA from the largest cervical lymph node measuring 15X13 mm No -
Hematology/Oncology
Hematology/Oncology Description: The pediatric hematology-oncology division sees a wide spectrum of pediatric disease including but not limited to leukemia, hemophilia, solid tumors, ITP, and other blood dyscrasias. The pediatric resident is expected to be involved in the work-up and on-going management of all patient presenting to the hem-onc service. Note: The goals and objectives described in detail below are not meant to be completed in a single one month block rotation but are meant to be cumulative, culminating in a thorough and complete Pediatric Hem-Onc experience at the end of residency. Primary Goals for this Rotation GOAL: Prevention, Counseling and Screening. Understand the role of the pediatrician in preventing hematologic or oncologic conditions, and in counseling and screening individuals at risk for these diseases. Provide routine preventive counseling about hematology to all patients and families, addressing: 1. Adequate diet and iron intake to prevent iron deficiency 2. Signs and symptoms of malignant disease Provide preventive counseling to parents and patients with specific hematology/oncology conditions, addressing: 1. In a child with a sickle hemoglobinopathy, the importance of antibiotic prophylaxis, pneumococcal and routine immunizations, folic acid supplementation, and urgent need for evaluation for fever 2. Risk of infections related to transfusion of blood or blood products, and alternatives to routine transfusion (i.e., direct donation, irradiation, freezing, filtration) 3. Expected course of common childhood malignancies, with good and bad prognosticators 4. Support groups and information available for children with cancer Provide regular hematology/oncology screening for patients: 1. Screen for hemoglobinopathies in the newborn period. -
Transplantation Antitumor Activity After Bone Marrow Graft-Versus-Host
The Journal of Immunology Host NKT Cells Can Prevent Graft-versus-Host Disease and Permit Graft Antitumor Activity after Bone Marrow Transplantation1 Asha B. Pillai,* Tracy I. George,† Suparna Dutt,* Pearline Teo,* and Samuel Strober2* Allogeneic bone marrow transplantation is a curative treatment for leukemia and lymphoma, but graft-vs-host disease (GVHD) remains a major complication. Using a GVHD protective nonmyeloablative conditioning regimen of total lymphoid irradiation and antithymocyte serum (TLI/ATS) in mice that has been recently adapted to clinical studies, we show that regulatory host NKT cells prevent the expansion and tissue inflammation induced by donor T cells, but allow retention of the killing activity of donor T cells against the BCL1 B cell lymphoma. Whereas wild-type hosts given transplants from wild-type donors were protected against progressive tumor growth and lethal GVHD, NKT cell-deficient CD1d؊/؊ and J␣-18؊/؊ host mice given wild-type transplants cleared the tumor cells but died of GVHD. In contrast, wild-type hosts given transplants from CD8؊/؊ or perforin؊/؊ donors had progressive tumor growth without GVHD. Injection of host-type NKT cells into J␣-18؊/؊ host mice conditioned with TLI/ATS markedly reduced the early expansion and colon injury induced by donor T cells. In conclusion, after TLI/ATS host conditioning and allogeneic bone marrow transplantation, host NKT cells can separate the proinflammatory and tumor cytolytic functions of donor T cells. The Journal of Immunology, 2007, 178: 6242–6251. raft-vs-host disease (GVHD)3 remains a major compli- taining antitumor activity. Preclinical studies of a TLI and anti- cation of human hemopoietic cell transplantation in the thymocyte serum (ATS) regimen in mice showed that the G treatment of leukemia and lymphoma (1). -
Post-Splenectomy Sepsis: a Review of the Literature
Open Access Review Article DOI: 10.7759/cureus.6898 Post-splenectomy Sepsis: A Review of the Literature Faryal Tahir 1 , Jawad Ahmed 1 , Farheen Malik 2 1. Internal Medicine, Dow University of Health Sciences, Karachi, PAK 2. Pediatrics, Dow University of Health Sciences, Karachi, PAK Corresponding author: Jawad Ahmed, [email protected] Abstract The spleen is an intraperitoneal organ that performs vital hematological and immunological functions. It maintains both innate and adaptive immunity and protects the body from microbial infections. The removal of the spleen as a treatment method was initiated from the early 1500s for traumatic injuries, even before the physiology of spleen was properly understood. Splenectomy has therapeutic effects in many conditions such as sickle cell anemia, thalassemia, idiopathic thrombocytopenic purpura (ITP), Hodgkin’s disease, and lymphoma. However, it increases the risk of infections and, in some cases, can lead to a case of severe sepsis known as overwhelming post-splenectomy infection (OPSI), which has a very high mortality rate. Encapsulated bacteria form a major proportion of the invading organisms, of which the most common is Streptococcus pneumoniae. OPSI is a medical emergency that requires prompt diagnosis (with blood cultures and sensitivity, blood glucose levels, renal function tests, and electrolyte levels) and management with fluid resuscitation along with immediate administration of empirical antimicrobials. OPSI can be prevented by educating patients, vaccination, and antibiotic prophylaxis.